Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Evolution of quality of life in patients with breast cancer during the first year of follow-up in Morocco

Authors: B. M. Traore, S. El Fakir, H. Charaka, N. Benaicha, A. Najdi, A. Zidouh, M. Bennani, H. Errihani, N. Mellass, A. Benider, R. Bekkali, C. Nejjari

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Quality of life has an important place in the future of patients with breast cancer. The objective of this study is to assess the evolution of the patient’s quality of life with breast cancer in Morocco after a year of follow-up.

Methods

This study involved the patients with breast cancer with all types of treatment as determined by their physicians. Patient’s quality of life was assessed with the Moroccan Arabic version of QLQ- EORTC QLQ C30 and EORTC-BR23 questionnaires. Data were analyzed using SPSS Version 20 software.

Results

Regarding EOTRC questionnaires QLQ C-30, there was a significant improvement in global health status and all scales of the functional dimension except the social functional where there was a trend towards improvement and the financial impact of the disease where the situation has deteriorated. Quality of life was improved for most symptom-sized scales dimension of EORTC QLQ- C30 with the exception of diarrhea where it was observed degradation. Most of the EORTC QLQ-scales BR23 questionnaires showed a favorable trend in the quality of life except those of sexual functioning, sexual enjoyment, hair loss and the side effects of systemic therapy.

Conclusion

The quality of life of the patient is significantly improved after 1 year of follow up. Quality of life instruments can be useful in the early identification of patients whose score low on functional scales and symptoms.
Literature
1.
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–92.CrossRefPubMed
2.
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed
3.
Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, La Vecchia C. The decline in breast cancer mortality in Europe: an update (to 2009). Breast. 2012;1:77–82.CrossRef
4.
Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, et al. EORTC clinical groups. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10(9):865–71.CrossRefPubMed
5.
Montazeri A, Gillis CR, McEwen J. Measuring quality of life in oncology: is it worthwhile? Part I. Meaning, purposes, and controversies. Eur J Cancer Care. 1996;5:159–67.CrossRef
6.
Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008;27(1):32.CrossRefPubMedPubMedCentral
7.
Holzner B, Bode RK, Hahn EA, Cella D, Kopp M, Sperner-Unterweger B, et al. Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research. Eur J Cancer. 2006;42(18):3169–77.CrossRefPubMed
8.
Staren ED, Gupta D, Braun DP. The prognostic role of quality of life assessment in breast cancer. Breast J. 2011;17:571–8.CrossRefPubMed
9.
El Fakir S, Abda N, Bendahhou K, Zidouh A, Bennani M, Errihani H and al. The European Organization for Research and Treatment of cancer quality of life questionnaire-BR23 breast cancer-specific quality of life questionnaire: psychometric properties in a Moroccan sample of breast cancer patients. BMC Res Notes. 2014 7:53.
10.
Ganz PA, Kwan L, Stanton AL, Krupnick JL, Rowland JH, Meyerowitz BE, et al. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst. 2004;96:376–87.CrossRefPubMed
11.
David M-V, Salvador P, Elvira B-V, Antonio C-G, M. Dolores M-M, Ángel M-A et al. Evolution of Health-Related Quality of Life in Breast Cancer Patients during the First Year of Follow-Up. J Breast Cancer 2013; 16(1): 104-111.
12.
Kristin H, Jutta E, Peter H, Hans R, Harald S, Klaus F. Personality traits and psychosocial stress: quality of life over 2 years following breast cancer diagnosis and psychological impact factors. Psycho-Oncology. 2010;19:160–9.CrossRef
13.
Kornblith AB, Herndon JE 2nd, Weiss RB, Zhang C, Zuckerman EL, Rosenberg S, et al. Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer. 2003;98(4):679–89.CrossRefPubMed
14.
Liu Y, Perez M, Schootman M, Aft RL, Gillanders WE, Jeffe DB. Correlates of fear of cancer recurrence in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat. 2011;130(1):165–73.CrossRefPubMedPubMedCentral
15.
Brédart A, Dolbeault S, Savignoni A, Besancenet C, This P, Giami A, et al. Prevalence and associated factors of sexual problems after early-stage breast cancer treatment: results of a French exploratory survey. Psychooncology. 2011;20(8):841–50.CrossRefPubMed
16.
Metadata
Title
Evolution of quality of life in patients with breast cancer during the first year of follow-up in Morocco
Authors
B. M. Traore
S. El Fakir
H. Charaka
N. Benaicha
A. Najdi
A. Zidouh
M. Bennani
H. Errihani
N. Mellass
A. Benider
R. Bekkali
C. Nejjari
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4008-3

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Body mass index and lung cancer risk: a pooled analysis based on nested case-control studies from four cohort studies

Research article

Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study

Research article

Development of the body image self-rating questionnaire for breast cancer (BISQ-BC) for Chinese mainland patients

Research article

Predominance of triple wild-type and IGF2R mutations in mucosal melanomas

Research article

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel

Research article

Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits